• D-Luciferin Potassium Salt for BLI Workflows

  2026-08-12

  D-Luciferin potassium salt turns firefly luciferase expression into a practical, non-invasive readout for tumor cell tracking, mRNA delivery studies, ATP assays, and reporter screening. Its water solubility and compatibility with in vivo bioluminescence imaging make it especially useful when repeated measurements are more informative than terminal sampling.

• Azilsartan Medoxomil: AT1 Binding and BP Control

  2026-08-11

  This literature review identifies persistent AT1-receptor interaction as the distinguishing pharmacological feature of azilsartan medoxomil, linking washout-resistant binding with clinically meaningful blood-pressure reduction. Its evidence synthesis supports further essential hypertension treatment research while emphasizing that improved surrogate endpoints have not yet established a mortality benefit.

• IGF2BP1–TUBB4B Axis in Liver Fibrosis

  2026-08-10

  The reference study identifies an m6A-dependent mechanism in which IGF2BP1 stabilizes TUBB4B mRNA and promotes hepatic stellate cell activation through FAK signaling. Its integrated sequencing, RNA-binding, genetic, and pharmacological evidence provides a useful framework for studying methylation-linked fibrogenesis while highlighting the need for further in vivo and disease-context validation.

• Anlotinib hydrochloride Workflows

  2026-08-09

  Build more informative angiogenesis assays with Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor that connects receptor phosphorylation, ERK signaling, endothelial migration, and tube formation. This guide translates preclinical evidence into practical workflows, controls, and troubleshooting strategies for cancer research.

• IGF2BP1 Stabilizes TUBB4B in Liver Fibrosis

  2026-08-08

  The reference study identifies an m6A-dependent IGF2BP1–TUBB4B–FAK pathway that promotes hepatic stellate cell activation, proliferation, and migration. Its integrated transcriptomic and cellular strategy provides a useful framework for connecting RNA modification readers with fibrogenic signaling, while also highlighting the need for orthogonal genetic and pharmacological validation.

• Tacalcitol monohydrate: Applied Lab Workflows

  2026-08-07

  Translate VDR biology into reproducible NGF, keratinocyte, and colorectal cancer assays with Tacalcitol monohydrate. This workflow-focused guide covers concentration selection, 5-fluorouracil combination studies, controls, storage, and troubleshooting.

• T7 RNA Polymerase: Recombinant Enzyme for Precision RNA Synt

  2026-08-07

  T7 RNA Polymerase is a recombinant enzyme expressed in E. coli, renowned for its high specificity to T7 promoter sequences and broad utility in in vitro transcription. It enables efficient RNA synthesis from linearized plasmid templates, supporting applications from RNA vaccine production to RNAi research. APExBIO’s K1083 enzyme offers reliable and scalable solutions for molecular biology workflows.

• Crystal Violet Staining Solution: Reliable Workflows for Cel

  2026-08-06

  This scenario-driven guide details how Crystal Violet Staining Solution (SKU K1184) addresses common laboratory challenges in nuclear staining and cell-based assays. The article explores real-world use cases, protocol optimization, and vendor selection, providing evidence-backed recommendations for biomedical researchers and laboratory technicians.

• Estradiol: Precision Mechanisms and Translational Impact in

  2026-08-06

  Explore the multifaceted mechanisms of estradiol in organ protection, emphasizing estrogen receptor signaling and autophagy pathways. This article provides new assay insights and a translational perspective, setting it apart from existing research guides.

• CUDC-907: Technical Guide for Dual PI3K and HDAC Inhibition

  2026-08-05

  CUDC-907 is a dual PI3K and HDAC inhibitor that enables simultaneous modulation of cancer-relevant signaling and epigenetic pathways in cell-based research. It is suitable for controlled in vitro workflows requiring precise pathway inhibition, but is not intended for diagnostic, therapeutic, or clinical use.

• CFDA SE Cell Tracer Kit: Practical Guide for Stable Cell Tra

  2026-08-05

  The CFDA SE (carboxyfluorescein diacetate succinimidyl ester) Cell Tracer Kit provides a robust, lasting method for covalent fluorescent labeling in cell proliferation and lineage tracing workflows. It is optimal for long-term cell tracking in both in vitro and in vivo studies, but is not suitable for short-term or reversible labeling protocols. Researchers should use this kit when persistent, stable fluorescence and minimal cytotoxicity are essential.

• Extracellular Vesicle-Transferred ACLY Drives TAM Differenti

  2026-08-04

  This study reveals that hepatocellular carcinoma (HCC) cells release extracellular vesicles containing ATP-citrate lyase (ACLY), which are internalized by monocytes and induce their differentiation into immunosuppressive tumor-associated macrophages (TAMs). By elucidating a lipid metabolism-dependent mechanism of immune modulation in the tumor microenvironment, the research suggests new strategies for enhancing immunotherapeutic efficacy in HCC.

• WEHI-539: Strategic BCL-XL Inhibition for Translational Rese

  2026-08-04

  This thought-leadership article explores how WEHI-539, a selective BCL-XL inhibitor from APExBIO, enables translational researchers to dissect apoptosis pathways, confront chemoresistance in cancer stem cells, and design more predictive preclinical models. By integrating mechanistic insight, protocol strategies, and competitive benchmarking, the article provides actionable guidance for leveraging WEHI-539 to advance the science and translational impact of apoptosis research.

• Targeting Methylation Pathways in Hepatic Stellate Cells: A

  2026-08-03

  This thought-leadership article explores how precise inhibition of S-adenosylhomocysteine hydrolase with 3-Deazaadenosine hydrochloride can advance translational research into hepatic stellate cell activation and liver fibrosis. Drawing on recent mechanistic insights into m6A-dependent regulation of TUBB4B by IGF2BP1, we outline the opportunities and best practices for researchers to dissect and modulate methyltransferase-driven fibrogenic signaling.

• Strategic Translation of Iptacopan (LNP023) for Complement P

  2026-08-03

  This thought-leadership article synthesizes mechanistic insights and strategic guidance for translational researchers utilizing Iptacopan (LNP023) in complement activation studies. Integrating recent clinical advances, protocol optimization, and risk prediction models, it offers a roadmap to maximize the translational impact of alternative pathway C3bBb inhibition—bridging the gap between preclinical discovery and clinical application.

461 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page